<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=137257"><dc:title>Cervical intraepithelial neoplasia grade 3 in a HPV-vaccinated patient</dc:title><dc:creator>Sladič,	Mateja	(Avtor)
	</dc:creator><dc:creator>Taneska,	Pepita	(Avtor)
	</dc:creator><dc:creator>Cvjetičanin,	Branko	(Avtor)
	</dc:creator><dc:creator>Velikonja,	Mojca	(Avtor)
	</dc:creator><dc:creator>Smrkolj,	Vladimir	(Avtor)
	</dc:creator><dc:creator>Smrkolj,	Špela	(Avtor)
	</dc:creator><dc:subject>papillomavirus vaccines</dc:subject><dc:subject>Papanicolaou test</dc:subject><dc:subject>cervical intraepithelial neoplasia</dc:subject><dc:description>Persistent infection with human papillomavirus (HPV) causes almost all cervical precancerous lesions and cancers. Bivalent, quadrivalent, and nonavalent HPV vaccines effectively prevent high-grade cervical intraepithelial neoplasia (CIN3). The effectiveness of HPV vaccination against CIN3 is 97–100% in HPV-naïve populations and 44–61% in the overall population. Although HPV vaccination has substantially reduced the incidence of cervical cancers, several cases of precancerous cervical lesions in HPV-vaccinated patients have been reported. We report the clinical case of a 19-year-old woman whose first Pap smear was diagnosed as a high-grade squamous intraepithelial lesion (HSIL) after quadrivalent HPV vaccination. Colposcopy and cervical biopsy were performed, revealing HSIL/CIN3. Our multidisciplinary team decided to take a conservative approach with follow-up visits with cervical biopsies of this young patient. After six months, spontaneous regression of high-grade cervical dysplasia was observed. Although HPV immunization has shown to be extremely effective in preventing a high proportion of cervical precancerous lesions and cervical cancers, HPV vaccines do not protect against all oncogenic high-risk HPV genotypes. Consequently, healthcare providers must encourage HPV-vaccinated women to still regularly attend national cervical screening programs.</dc:description><dc:date>2022</dc:date><dc:date>2022-06-08 12:15:13</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>137257</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
